{"id":"NCT01435460","sponsor":"Bausch & Lomb Incorporated","briefTitle":"Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)","officialTitle":"A Clinical Safety and Efficacy Evaluation of Alrex® (Loteprednol Etabonate Ophthalmic Suspension, 0.2%) Versus Patanol (Olopatadine Hydrochloride Ophthalmic Solution, 0.1%) in the Treatment of Seasonal Allergic Conjunctivitis (SAC)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08","primaryCompletion":"2011-04","completion":"2011-05","firstPosted":"2011-09-16","resultsPosted":"2012-03-13","lastUpdate":"2012-03-13"},"enrollment":300,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Seasonal Allergic Conjunctivitis"],"interventions":[{"type":"DRUG","name":"Loteprednol etabonate 0.2%","otherNames":["Alrex"]},{"type":"DRUG","name":"Olopatadine 0.1%","otherNames":["Patanol"]}],"arms":[{"label":"Alrex","type":"EXPERIMENTAL"},{"label":"Patanol","type":"ACTIVE_COMPARATOR"}],"summary":"This study is to evaluate the safety and efficacy of Alrex (LE ophthalmic suspension, 0.2%) versus Patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief of the signs and symptoms of Seasonal Allergic Conjunctivitis (SAC).","primaryOutcome":{"measure":"Bulbar Conjunctival Injection","timeFrame":"Change from baseline to day 15 (visit 3)","effectByArm":[{"arm":"Alrex","deltaMin":-1.91,"sd":0.521},{"arm":"Patanol","deltaMin":-1.71,"sd":0.585}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":1,"countries":["Singapore"]},"refs":{"pmids":["22627057"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":151},"commonTop":[]}}